Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 422)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Valganciclovir |
Approved, Investigational |
Phase 4 |
|
175865-60-8 |
64147 |
Synonyms:
Cymeval
Ganciclovir L-valyl ester
L-Valine, ester with ganciclovir
RO-1079070/194
RS-079070-194
|
Valcyt
Valcyte
VALGANCICLOVIR
Valganciclovir hydrochloride
|
|
2 |
|
Rituximab |
Approved |
Phase 4 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
3 |
|
Chlorambucil |
Approved |
Phase 4 |
|
305-03-3 |
2708 |
Synonyms:
4-(Bis(2-chloroethyl)amino)benzenebutanoic acid
4-(p-Bis(b-chloroethyl)aminophenyl)butyrate
4-(p-Bis(b-chloroethyl)aminophenyl)butyric acid
4-(p-Bis(beta-chloroethyl)aminophenyl)butyrate
4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid
4-(p-Bis(β-chloroethyl)aminophenyl)butyrate
4-(p-Bis(β-chloroethyl)aminophenyl)butyric acid
4-[p-[Bis(2-chloroethyl)amino]phenyl]butyrate
4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid
Ambochlorin
Amboclorin
CB-1348
Chlocambucil
CHLORAMBUCIL
Chloraminophen
Chloraminophene
Chlorbutin
Chlorbutine
Chloroambucil
Chlorobutin
Chlorobutine
Clorambucilo
Ecloril
Elcoril
g-[p-Di(2-chloroethyl)aminophenyl]butyrate
g-[p-Di(2-chloroethyl)aminophenyl]butyric acid
|
gamma-[p-Di(2-chloroethyl)aminophenyl]butyrate
gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid
Glaxo wellcome brand OF chlorambucil
GlaxoSmithKline brand OF chlorambucil
Leukeran
Leukeran Tablets
Leukersan
Leukoran
Linfolizin
Linfolysin
Lympholysin
N,N-Di-(2-chloroethyl)-p-aminophenylbutyric acid
N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyrate
N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid
N,N-Di-2-chloroethyl-g-p-aminophenylbutyrate
N,N-Di-2-chloroethyl-g-p-aminophenylbutyric acid
N,N-Di-2-chloroethyl-γ-p-aminophenylbutyrate
N,N-Di-2-chloroethyl-γ-p-aminophenylbutyric acid
NCI-3088
NSC-3088
Pepstatin
Phenylbutyrate nitrogen mustard
Phenylbutyric acid nitrogen mustard
Wellcome brand OF chlorambucil
Γ-[p-di(2-chloroethyl)aminophenyl]butyrate
Γ-[p-di(2-chloroethyl)aminophenyl]butyric acid
|
|
4 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
5 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
6 |
|
Epoetin Alfa |
|
Phase 4 |
|
|
|
Synonyms:
BINOCRIT
EPO
EPOETIN ALFA
EPOGEN
|
EPREX
ERYTHROPOIETIN PRECURSOR
PROCRIT
|
|
7 |
|
Hematinics |
|
Phase 4 |
|
|
|
8 |
|
Chrysarobin |
|
Phase 4 |
|
|
|
9 |
|
Cladribine |
Approved, Investigational |
Phase 3 |
|
4291-63-8 |
20279 |
Synonyms:
(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2-CdA
2-Chloro-2'-deoxyadenosine
2-Chloro-2'-deoxy-b-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxy-β-adenosine
2-Chloro-6-amino-9-(2-deoxy-b-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine
2-Chlorodeoxyadenosine
2-Chloro-deoxyadenosine
2ClAdo
2'-Deoxy-2-chloroadenosine
Chlorodeoxyadenosine
|
CLADARIBINE
Cladribina
CLADRIBINE
Cladribinum
CldAdo
LEUSTAT
Leustatin
LITAK
Mavenclad
Mylinax
NSC-05014
NSC-105014
NSC-105014-F
RWJ-26251
|
|
10 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
11 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 3 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
12 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
13 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
14 |
|
Iron |
Approved |
Phase 3 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
15 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3 |
|
209810-58-2 |
|
Synonyms:
ARANESP
ARANESP SURECLICK
Darbepoetin
DARBEPOETIN ALFA
Darbepoetin alfa,recombinant
Darbepoetina alfa
|
EPOETIN
ERYTHROPOIETIN PRECURSOR
KRN321
KRN-321
NESP
|
|
16 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
17 |
|
Acalabrutinib |
Approved, Investigational |
Phase 3 |
|
1420477-60-6 |
71226663 71226662 |
Synonyms:
ACALABRUTINIB
Acalabrutinibum
ACP-196
|
ACP-196|Calquence®|Example 6 [US20140155385 A1]
CALQUENCE
EXAMPLE 6 [US20140155385 A1]
|
|
18 |
|
Fludarabine |
Approved |
Phase 3 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
19 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
20 |
|
Vidarabine |
Approved, Investigational |
Phase 3 |
|
24356-66-9 |
21704 |
Synonyms:
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
9 beta Arabinofuranosyladenine
9 beta D Arabinofuranosyladenine
9-b-D-Arabinofuranosyl-9H-purin-6-amine
9-b-D-Arabinofuranosyladenine
9-beta-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-adenine
9-Î’-D-arabinofuranosyl-9H-purin-6-amine
9-Î’-D-arabinofuranosyladenine
a, alpha-Ara
a, Ara
a, beta-Ara
Adenine arabinoside
alpha Ara a
alpha D Arabinofuranosyladenine
alpha-Ara a
alpha-D-Arabinofuranosyladenine
Ara a
ARA-a
Araadenosine
|
Ara-ATP
Arabinofuranosyladenine
Arabinoside adenine
Arabinoside, adenine
Arabinosyl adenine
Arabinosyladenine
Armes
beta Ara a
beta-Ara a
CI-673
Monarch brand OF vidarabine
NSC-247519
NSC-404241
Parke davis brand OF vidarabine
Spongoadenosine
Vidarabine
Vidarabine anhydrous
VIDARABINE MONOHYDRATE
Vidarabinum
Vira a
Vira-a
ViraA
|
|
21 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
22 |
|
Triamcinolone |
Approved, Vet_approved |
Phase 3 |
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
23 |
|
Pancrelipase |
Approved, Investigational |
Phase 3 |
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
24 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
25 |
|
Mitoxantrone |
Approved, Investigational |
Phase 3 |
|
70476-82-3, 65271-80-9 |
4212 |
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
Acetate, mitoxantrone
AHP brand OF mitoxantrone hydrochloride
Amgen brand OF mitoxantrone hydrochloride
ASTA medica brand OF mitoxantrone hydrochloride
Baxter oncology brand OF mitoxantrone hydrochloride
CL-232315
CL-232315|Novantrone®
Columbia brand OF mitoxantrone hydrochloride
DHAD
DHAQ
DHAQ HCl
Dihydroxyanthraquinone
Hydrochloride, mitoxantrone
Inibsa brand OF mitoxantrone hydrochloride
Lederle brand OF mitoxantrone hydrochloride
Misostol
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
|
Mitoxantrona [INN-Spanish]
MITOXANTRONE
Mitoxantrone 2HCl
Mitoxantrone acetate
MITOXANTRONE DIHCL
MITOXANTRONE DIHYDROCHLORIDE
MITOXANTRONE HCL
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
Mitroxone
Novantron
Novantrone
NSC-279836
NSC-301739
Onkotrone
Pralifan
Ralenova
Wyeth brand OF mitoxantrone hydrochloride
|
|
26 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
27 |
|
Tenofovir |
Experimental, Investigational |
Phase 3 |
|
147127-20-6, 202138-50-9 |
464205 6398764 |
Synonyms:
(E)-but-2-enedioic acid
(R)-9-(2-PHOSPHONOMETHOXYPROPYL)ADENINE
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
Anh. tenofovir
Anhydrous tenofovir
Apropovir
ATRIPLA
bis({[(propan-2-yloxy)carbonyl]oxy}methyl) ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate (2E)-but-2-enedioate
D,L-Tenofovir
|
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GS-1275
GS-1278
PMPA
PMP-A
TDF
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TRUVADA
Viread
|
|
28 |
|
Reverse Transcriptase Inhibitors |
|
Phase 3 |
|
|
|
29 |
|
Cyclosporins |
|
Phase 3 |
|
|
|
30 |
|
Antifungal Agents |
|
Phase 3 |
|
|
|
31 |
|
Ferric Oxide, Saccharated |
|
Phase 3 |
|
|
|
32 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
33 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
34 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
35 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
36 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
37 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
38 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
39 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
40 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
41 |
|
Folate |
|
Phase 3 |
|
|
|
42 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
43 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
44 |
|
Caseins |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Triamcinolone hexacetonide |
|
Phase 3 |
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
46 |
|
Triamcinolone diacetate |
|
Phase 3 |
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
47 |
|
Triamcinolone Acetonide |
|
Phase 3 |
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
48 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
49 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
50 |
|
Paraproteins |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1243)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. |
Unknown status |
NCT00131313 |
Phase 4 |
Nipent, Cytoxan, Rituxan |
2 |
The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia |
Completed |
NCT00524407 |
Phase 4 |
Epoetin alfa |
3 |
A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia |
Completed |
NCT00220311 |
Phase 4 |
Fludarabine Phosphate (Fludara) |
4 |
A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia |
Completed |
NCT01056510 |
Phase 4 |
bendamustine;chlorambucil;rituximab [MabThera/Rituxan] |
5 |
Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study |
Completed |
NCT01255644 |
Phase 4 |
Valganciclovir |
6 |
The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL |
Completed |
NCT00919321 |
Phase 4 |
|
7 |
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma |
Active, not recruiting |
NCT04930536 |
Phase 4 |
Acalabrutinib capsule |
8 |
A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion |
Active, not recruiting |
NCT03190330 |
Phase 4 |
Ibrutinib 420 mg;Ibrutinib 560 mg |
9 |
Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of Revaccination |
Active, not recruiting |
NCT05316831 |
Phase 4 |
|
10 |
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens |
Not yet recruiting |
NCT04790045 |
Phase 4 |
Venetoclax |
11 |
Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment |
Terminated |
NCT02608060 |
Phase 4 |
Epoetin Beta |
12 |
Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status |
Terminated |
NCT01283386 |
Phase 4 |
Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab |
13 |
Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status |
Terminated |
NCT01271010 |
Phase 4 |
Cyclophosphamide;Fludarabine;Rituximab |
14 |
A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL |
Unknown status |
NCT01678430 |
Phase 3 |
Ofatumumab;Chlorambucil;Bendamustine |
15 |
Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers |
Unknown status |
NCT02991638 |
Phase 3 |
Ibrutinib |
16 |
Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients |
Unknown status |
NCT01657955 |
Phase 3 |
Bendamustine Hydrochloride Injection;Chlorambucil |
17 |
Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) |
Unknown status |
NCT00017108 |
Phase 3 |
chlorambucil;cyclophosphamide;fludarabine phosphate |
18 |
Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia |
Unknown status |
NCT01670812 |
Phase 3 |
FFP+HDMP+Rituximab |
19 |
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia |
Unknown status |
NCT02186574 |
Phase 3 |
Tenofovir disoproxil;Placebo Oral Tablet |
20 |
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL |
Unknown status |
NCT02475681 |
Phase 3 |
Acalabrutinib;Obinutuzumab;Chlorambucil |
21 |
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia |
Completed |
NCT00769522 |
Phase 3 |
Bendamustine;Cyclophosphamide;Fludarabine |
22 |
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia |
Completed |
NCT00281918 |
Phase 3 |
Rituximab;Cyclophosphamide;Fludarabine Phosphate |
23 |
An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL) |
Completed |
NCT01313689 |
Phase 3 |
Ofatumumab;Physicians' Choice |
24 |
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial |
Completed |
NCT01231412 |
Phase 3 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus |
25 |
INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation |
Completed |
NCT00799461 |
Phase 3 |
|
26 |
A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Completed |
NCT01973387 |
Phase 3 |
Rituximab;Ibrutinib |
27 |
Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO |
Completed |
NCT00645606 |
Phase 3 |
|
28 |
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT02756611 |
Phase 3 |
Venetoclax |
29 |
A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia |
Completed |
NCT00824265 |
Phase 3 |
OFC Infusion;FC infusion |
30 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) |
Completed |
NCT00774345 |
Phase 3 |
Lenalidomide;Placebo |
31 |
A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia |
Completed |
NCT01892618 |
Phase 3 |
Prevenar 13;Pneumovax |
32 |
A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 |
Completed |
NCT02049515 |
Phase 3 |
IPI-145 (duvelisib);Ofatumumab |
33 |
A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Completed |
NCT02264574 |
Phase 3 |
Ibrutinib;Obinutuzumab;Chlorambucil |
34 |
A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia |
Completed |
NCT00718549 |
Phase 3 |
Cladribine;Cyclophosphamide;Rituximab |
35 |
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO) |
Completed |
NCT02004522 |
Phase 3 |
Duvelisib;Ofatumumab |
36 |
A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia |
Completed |
NCT01905943 |
Phase 3 |
Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab |
37 |
A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab |
Completed |
NCT02005471 |
Phase 3 |
Bendamustine;Venetoclax;Rituximab |
38 |
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT02980731 |
Phase 3 |
Venetoclax |
39 |
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT02301156 |
Phase 3 |
Ublituximab;Ibrutinib |
40 |
A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity |
Completed |
NCT03730129 |
Phase 2, Phase 3 |
Hizentra |
41 |
Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia |
Completed |
NCT00262795 |
Phase 3 |
Fludarabine;Chlorambucil |
42 |
Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity |
Completed |
NCT00281892 |
Phase 3 |
Fludarabine mono |
43 |
Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia |
Completed |
NCT00262782 |
Phase 3 |
Fludarabine |
44 |
A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia |
Completed |
NCT00254163 |
Phase 3 |
Fludarabine;Cyclophosphamide;Rituximab;Pentostatin |
45 |
Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) |
Completed |
NCT00276848 |
Phase 3 |
Fludarabine plus Cyclophosphamide;Fludarabine |
46 |
Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia |
Completed |
NCT00024440 |
Phase 3 |
cyclophosphamide;fludarabine phosphate |
47 |
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Completed |
NCT01611090 |
Phase 3 |
Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo |
48 |
Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia |
Completed |
NCT00003764 |
Phase 3 |
cyclophosphamide;fludarabine phosphate |
49 |
International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia |
Completed |
NCT01118234 |
Phase 3 |
Rituximab |
50 |
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia |
Completed |
NCT00046683 |
Phase 3 |
alemtuzumab |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
|
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard
|
|